Robert A. Gabbay, MD, PhD, FACP, chief medical officer at Joslin Diabetes Center, moderates a discussion on the role of combination therapy in several ways, including early aggressive therapy with combination treatment and the combination of taking 2 medications in 1 tablet to encourage adherence with increased convenience and reduced copays. He is joined by S. Sethu K. Reddy, MD, MBA, FRCPC, FACP, MACE; Ravi Retnakaran, MD, MSc, FRCPC; Alexander Turchin, MD, MS; and Helen Feit, MD.
%jwplayer%
Robert A. Gabbay, MD, PhD, FACP, chief medical officer at Joslin Diabetes Center, moderates a discussion on the role of combination therapy in several ways, including early aggressive therapy with combination treatment and the combination of taking 2 medications in 1 tablet to encourage adherence with increased convenience and reduced copays. He is joined by S. Sethu K. Reddy, MD, MBA, FRCPC, FACP, MACE; Ravi Retnakaran, MD, MSc, FRCPC; Alexander Turchin, MD, MS; and Helen Feit, MD.
Dr Reddy has found that patients in his practice reaching their ABC goals were on 7 to 8 different medications. He adds that there are numerous reasons why a patient may be hyperglycemic; “it makes intuitive sense that no single drug or single mechanism is going to totally affect [him or her.]” However, Dr Reddy notes that this is a very complicated regime as patients grow older, which he believes impacts quality of life and adherence.
“With combination therapies, we have the potential for sub-maximal doses and lesser side effects,” Dr Retnakaran says. “We also have the possibility of hitting multiple parts of the pathophysiology.”
Dr Retnakaran adds, “Maybe we need to think of diabetes very differently than we currently do and maybe we need to think more like oncologists think.”
Additionally, Dr Turchin notes the importance of acquiring empirical evidence for the benefits and risks that come along with combination therapies, which both the patients and the healthcare system would face.
Beyond Insulin: The Impact of Next-Generation Diabetes Technology
April 17th 2024Experts explain how new diabetes technologies like continuous glucose monitors are transforming care beyond intensive insulin therapy, offering personalized insights and improving outcomes for patients of all treatment levels.
Read More
How Can Employers Leverage the DPP to Improve Diabetes Rates?
February 15th 2022On this episode of Managed Care Cast, Jill Hutt, vice president of member services at the Greater Philadelphia Business Coalition on Health, explains the Coalition’s efforts to reduce diabetes rates through the Diabetes Prevention Program (DPP).
Listen
Balancing Care Access and Fragmentation for Better Outcomes in Veterans With Diabetes
April 22nd 2021The authors of a study in the April 2021 issue of The American Journal of Managed Care® discuss the possible reasons behind the link between care fragmentation and hospitalizations in veterans with diabetes, as well as potential opportunities to address disjointed care in the context of the widespread telehealth uptake seen during the COVID-19 pandemic.
Listen